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Introduction: Kratom (Mitragyna speciosa) is a tropical plant traditionally used as an
ethnomedicinal remedy for several conditions in South East Asia. Despite the
increased interest in its therapeutical benefits in Western countries, little scientific
evidence is available to support such claims, and existing data remain limited to
kratom's chronic consumption.
Objective: Our study aims to investigate (pre)clinical evidence on the efficacy of
kratom as a therapeutic aid and its safety profile in humans.
Methods: A systematic literature search using PubMed and the Medline database
was conducted between April and November 2020.
Results: Both preclinical (N = 57) and clinical (N = 18) studies emerged from our
search. Preclinical data indicated a therapeutic value in terms of acute/chronic pain
(N = 23), morphine/ethanol withdrawal, and dependence (N = 14), among other
medical conditions (N = 26). Clinical data included interventional studies (N = 2)
reporting reduced pain sensitivity, and observational studies (N = 9) describing the
association between kratom's chronic (daily/frequent) use and safety issues, in
terms of health consequences (e.g., learning impairment, high cholesterol level,
dependence/withdrawal).
Conclusions: Although the initial (pre)clinical evidence on kratom's therapeutic
potential and its safety profile in humans is encouraging, further validation in large,
controlled clinical trials is required.
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1 | INTRODUCTION
Kratom (Mitragyna speciosa, Rubiaceae family) is an indigenous
tropical tree from Southern East Asia (e.g., Malaysia, Thailand, Laos,
Cambodia), which also grows in East‐West Africa and Papua New
Guinea (Hassan et al., 2013; Kruegel and Grundmann, 2018). This
evergreen non‐seasonal plant is also known locally with other names,
such as Biak‐Biak, Ketum, Kakuam, Ithang, Thom, and Mambog (Hassan
et al., 2013; Veltri and Grundmann, 2019). It exerts stimulant
cocaine‐like effects in doses smaller than 5 g and sedative‐like effects
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at higher doses between 5 and 15 g (Cinosi et al., 2015; Eastlack
et al., 2020).
Kratom leaves are generally smoked, chewed, or brewed as an
herbal decoction (Hassan et al., 2013; Kruegel and Grund-
mann, 2018). It has been used traditionally for centuries to treat
several medical conditions like diarrhea and pain, to mitigate opioid
and alcohol withdrawal symptoms, to detoxify from other substances,
like cannabis or methamphetamine, to improve sexual desire, and to
combat fatigue (Grewal, 1932a; Hassan et al., 2013; Saref
et al., 2019a; Singh et al., 2017; Vicknasingam et al., 2010).
Kratom has recently gained popularity as an ethnomedicinal
remedy in Western countries, especially in the United States (US),
where it is sold online and elsewhere (e.g., gas station, specialty
shops) in different formulations, such as tablets, supplements, cap-
sules, or powder (Prozialeck et al., 2012; Tavakoli et al., 2016).
Several user‐based surveys revealed use to self‐treat acute/chronic
pain, among other psychiatric conditions, including opioid and sub-
stance use disorders (Bath et al., 2020; Coe et al., 2019; Garcia‐
Romeu et al., 2020; Grundmann, 2017). A case report also referred
to its successful use in alleviating COVID‐19 related pain (Metastasio
et al., 2020).
However, despite this increased scientific interest in kratom, the
evidence supporting such self‐reported claims is still lacking. It is
known that its psychoactive effects are mainly dependent on its
major metabolite 7‐OH‐mitragynine (7HMG) and mitragynine (MG),
which together account for 68% of all the alkaloids present in the
plant (Hassan et al., 2013; Kruegel and Grundmann, 2018; Shel-
lard, 1974; Takayama, 2004).
Mitragynine (IUPAC name (E)‐2‐[2S,3S,12bS)‐3‐ethyl‐8‐
methoxy‐1,2,3,4,6,7,12,12b‐octahydroindolo[2,3‐a]‐quinolizin‐2‐yl]‐
3‐methoxyprop‐2‐enoate) is an indole alkaloid Corynanthe‐type
having a monoterpene portion similarly to yohimbine and the psy-
chedelic substance voacangine (Han et al., 2020; Hassan et al., 2013;
Kong et al., 2017a; Ramanathan et al., 2015). It is insoluble in both
basic and aqueous solutions but possesses a high solubility in typical
organic solvents (e.g., acetone, acetic acid, alcohol, chloroform, and
diethyl‐ether) (Han et al., 2020; Kong et al., 2017a; Ramanathan
et al., 2015). It has intermediate lipophilicity and a high capacity to
cross the blood‐brain barrier (Yusof et al., 2019).
The compound has been described as a G‐protein biased atypical
opioid (Faouzi et al., 2020; Gutridge et al., 2020; Raffa et al., 2018)
that acts as mu‐ and delta‐opioid receptor agonist (Foss et al., 2020;
Matsumoto et al., 1996b, 2006), and kappa‐opioid receptor
antagonist‐like, without β‐arrestin recruitment (Kruegel et al., 2016;
Todd et al., 2020; Váradi et al., 2016). Mitragynine also possesses a
non‐opioid action through (α2) adrenergic receptors, adenosine
(A2A), dopamine (D2), and serotonin (5‐HT2A, 5‐HT2C, and 5‐HT7)
receptors (Harun et al., 2015; Hiranita et al., 2019; Matsumoto
et al., 1996a, 1996b, 1997).
The contribution of these receptors in the (acclaimed) effects of
kratom has yet to be determined. A drawback is that most of the
available data has been collected in users. It derives from online
surveys, drug fora, and case reports. Additionally, Ramachandram
et al. (2019) reported that the association between the pharmaco-
dynamics and ‐kinetics of mitragynine in (pre)clinical models had not
been studied yet.
Limited evidence has shown that the compound possesses a
biphasic elimination pattern after both oral (p.o.) (half‐life (T1/2):3–
9 h) and intravenous (i.v.) (T1/2:13 h) administration in rodents (Kong
et al., 2017b; Ya et al., 2019), and a large volume of distribution when
it was administered (i.v.) in dogs (Maxwell et al., 2020). On the other
side, mitragynine has been shown to follow a two compartmental
model after oral intake in a small sample of kratom users, with a T1/2
of 23.24 ± 16.07 h (Trakulsrichai et al., 2015).
The metabolism of mitragynine has been described to be mainly
hepatic in both human microsomes (Kamble et al., 2019) and pre-
clinical models (Ya et al., 2019), and it would be mediated by cyto-
chrome P450 (CYP450) (Basiliere and Kerrigan, 2020; Hanapi
et al., 2013; Kong et al., 2011), which may also be involved in po-
tential drug‐drug interaction.
Serious adverse events, including fatalities (Corkery et al., 2019;
Wong and Mun, 2020), have been reported only in Western coun-
tries, mainly when kratom is used in recreational settings. Suggested
reasons are extreme high dose, and co‐administration of benzodiaz-
epines, amphetamines, or ethanol, or the presence of adulterants, like
the synthetic O‐desmethyl tramadol (Anwar et al., 2016; Corkery
et al., 2019; Kronstrand et al., 2011; Olsen et al., 2019). Other serious
events have been associated with chronic kratom use (Alsarraf
et al., 2019; Anwar et al., 2016; Grundmann, 2017; Schimmel and
Dart, 2020) and include the risk of addiction, dependence, and
withdrawal (Singh et al., 2018c; Veltri and Grundmann, 2019).
The Food and Drug Administration (FDA) and the US Drug
Enforcement Administration (DEA) considered these kratom‐related
reports as dangerous and consequently proposed to place the plant
in Schedule I of the Controlled Substances Act (CSA) in 2016 (Eastlack
et al., 2020; Grundmann, 2017; Henningfield et al., 2018). However,
since a broad public opposition reversed this action, kratom is still legal
at the federal level in the US, with many users claiming its therapeutic
potential, in the absence of sufficient clinical evidence.
Given this background, the current systematic review aims to
investigate whether kratom has potential medical benefits based on
preclinical and clinical studies measuring acute and chronic effects on
behavior and other clinical outcomes. The second aim was to inves-
tigate possible safety issues in humans. The medical applications of
kratom reported by users in traditional and non‐traditional settings
were used to define this review's search strings.
2 | MATERIALS AND METHODS
2.1 | Data sources and search strategy
A literature search was performed using the PubMed and the Med-
line database to identify the scientific publications related to kra-
tom's potential therapeutic utility and safety, as investigated in (pre)
clinical research. The search, which was carried out between April
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and August 2020, consisted of assessing titles and abstracts using
both Medical Subject Headings, or subheadings (MeSH) and free‐text
terms. The choice of search terms was informed by recent high‐
quality reviews, papers, and online surveys that reported anecdotal
data related to kratom's benefits in treating pain, psychiatric symp-
toms and conditions, and several other medical applications (e.g.,
hypertension, inflammatory conditions, diabetes).
The query's search strings included a combination of substance
[1] and symptoms/condition [2] strings; both included the Boolean
command 'OR', and they were combined with 'AND'. The terms used
in [1] were kratom, mitragynine, mitragyna, Mitragyna speciosa. The
terms used in [2] were: ADD, addiction, ADHD, affective disorders,
analgesia, analgesic, analgesics, anorexia, anthelmintic, antidepres-
sant, anti‐inflammatory, antimalarial, antinociceptive, anxiety, anxio-
lytic, attention deficit disorder, attention deficit hyperactivity
disorder, bipolar disorder, blood pressure, cough, dependence,
depression, diabetes, diarrhea, diarrheal disease, fever, gastric,
infection, inflammation, mood disorders, “muscle AND relaxation”,
opioid use disorder, pain, psychosis, psychotic disorders, stress, stress
disorders post traumatic, substance‐related disorders, treatment‐
resistant depression, withdrawal. Terms in this string were com-
bined with ‘OR’. No period restrictions were applied. This search led
to 224 hits and was updated on November 2020, to identify records
that could have potentially been published during the preparation of
this paper for submission. This search gave 7 additional articles.
2.2 | Inclusion/exclusion criteria
Taking into account the review method and the aim of this study,
exclusion criteria were the following: (1) non‐original research arti-
cles or publications not pertinent or not potentially related to the
aims, including those mainly focused on methods of identification in
biological samples or sold products, chemistry and physicochemical
properties, pharmacology, including pharmacodynamic and pharma-
cokinetic properties, toxicology or other topics (fatalities, harm
reduction, legal status); (2) review, commentaries, or other surveys of
the literature; (3) case series and case reports because of their high
potential of bias in the study designs; (4) data in humans derived from
online surveys.
Studies were included if they met all of the following criteria: (1)
preclinical study, in vitro or in vivo, investigating the pharmacology or
toxicology potentially related to the review aim, and (2) any clinical
outcome providing sufficient scientific evidence of kratom, mitragy-
nine, mitragyna and related or derivative compounds, that would
support the traditional medical uses or anecdotal benefits reported
by users.
2.3 | Study selection
All procedures were performed according to PRISMA guidelines
(Moher et al., 2009). The selection was conducted in two stages: an
initial screening of titles and abstracts against the inclusion criteria to
identify potentially relevant papers, followed by screening the full
papers assessed for eligibility. The selection was discussed in a small
team of four (EP, ET, JR, KK).
2.4 | Data extraction
When a record reported a combination of review‐relevant and ‐
irrelevant data, only the former was included. Based on the included
articles' content, the review was organized in the following cate-
gories: (pre)clinical evidence related to potential therapeutic use in
pain, withdrawal and dependence, and other medical conditions, and
therapeutic application or safety issues in humans.
3 | RESULTS
3.1 | Studies description
In total, 63 studies met the eligibility criteria. After an initial
screening, 17 were removed, as they focused on Mitragyna genus per
se or on kratom pharmacology and toxicology data and thus not
relevant for this review. Additional studies (29) were included in the
analysis as a further assessment of relevant citations emerged.
Overall, 75 records were deemed relevant to this systematic review
(details of the selection process are shown in Figure 1). These
included 18 studies performed in humans, and 57 preclinical studies,
that were mainly in vivo studies with a brief observation period, with
nine having a more extended observation period (Cheaha et al., 2015;
Grewal, 1932b; Harun et al., 2020; Hassan et al., 2020; Khor
et al., 2011; Kumarnsit et al., 2006, 2007a; Meepong and Sooksa-
wate, 2019; Wilson et al., 2020), and other nine were in vitro (Abdul
Aziz et al., 2012; Fakurazi et al., 2013; Ghazali et al., 2011; Goh
et al., 2014; Grewal, 1932b; Jamil et al., 2013; Juanda et al., 2019;
Parthasarathy et al., 2009; Yuniarti et al., 2020). Since six preclinical
studies gave evidence for two potential therapeutic uses, the related
content will be described in each specific section of the results.
3.2 | (Pre)clinical evidence of potential therapeutic
use
3.2.1 | Pain
Twenty‐three in vivo (mice, rats, or dogs) studies provided evidence
for kratom's potential therapeutic use in the treatment of acute pain
(Carpenter et al., 2016; Criddle, 2015; Fakurazi et al., 2013; Hiranita
et al., 2019; Idid et al., 1998; Macko et al., 1972; Matsumoto
et al., 1996a, 1996b, 2004, 2005, 2006, 2008; Mossadeq et al., 2009;
Reanmongkol et al., 2007; Sabetghadam et al., 2010, 2013; Shamima
et al., 2012; Stolt et al., 2014; Takayama et al., 2002; Thongpra-
dichote et al., 1998; Wilson et al., 2020) and chronic pain
PREVETE ET AL. - 3 of 33
(Foss et al., 2020; Matsumoto et al., 2014). The antinociceptive ef-
fects of the studied preparations were shown in the different models
of acute thermal or mechanical stimulus‐induced pain, and neuro-
pathic pain, after administration via a range of routes (p.o., i.p., i.v., or
i.c.v.).
The studied preparations were Mitragyna speciosa (MS) aqueous
or methanol or alkaloid extracts (Carpenter et al., 2016; Crid-
dle, 2015; Mossadeq et al., 2009; Reanmongkol et al., 2007; Sabet-
ghadam et al., 2010, 2013), lyophilized kratom tea (LKT) (Wilson
et al., 2020), mitragynine alone (Carpenter et al., 2016; Criddle, 2015;
Fakurazi et al., 2013; Foss et al., 2020; Hiranita et al., 2019; Idid
et al., 1998; Macko et al., 1972; Matsumoto et al., 1996a, 1996b;
Shamima et al., 2012; Thongpradichote et al., 1998), or mitragy-
nine + paynantheine (Stolt et al., 2014), and its synthetic derivatives
MG Pseudoindoxyl (Takayama et al., 2002) and [(E)‐methyl 2‐(3‐
ethyl‐7a,12a‐(epoxyethanoxy)‐9‐fluoro‐1,2,3,4,6,7,12,12b‐octahydr
o‐8‐methoxyindolo[2,3‐a]quinolizin‐2‐yl)‐3‐methoxyacrylate] (MG
M‐9) (Matsumoto et al., 2008), or 7HMG (Matsumoto et al., 2004,







According to the evidence included in our analysis, mitragy-
nine's analgesic effect was similar to classical opioids oxycodone
and morphine (MOR) (Carpenter et al., 2016; Criddle, 2015). When
combined with MOR in long‐term treatment, the analgesic effect
was more pronounced (Fakurazi et al., 2013). Further, it was
described as more potent and relatively safer than the MS alkaloid
extract (Sabetghadam et al., 2013). Wilson et al. (2020) also found
LKT's analgesic effect similar to MOR, with relatively fewer nega-
tive effects (Wilson et al., 2020). 7HMG, a partial mu‐ and delta‐
F I GUR E 1 PRISMA flowchart depicting the selection and review process that resulted in 75 articles for inclusion in the current review
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opioid receptors agonist, was described as more potent than MOR
(Matsumoto et al., 2004, 2006), with a minor intestinal transit in-
hibition (Matsumoto et al., 2006). However, it was also found
responsible for a locomotor activity increase in a dose‐dependent
manner (Matsumoto et al., 2008) and producing cross‐tolerance
to MOR (Matsumoto et al., 2005, 2008). Among its derivatives,
authors found MGM‐16 to have a superior potency as an opioid
agonist in comparison to both MGM‐15 and 7HMG (Foss
et al., 2020; Matsumoto et al., 2014), and Matsumoto et al. (2008)
reported MGM‐9 to have higher potency, with lower adverse ef-
fects, whether compared to MOR and 7HMG (Matsumoto
et al., 2008).
Further, four studies (Fakurazi et al., 2013; Macko et al., 1972;
Mossadeq et al., 2009; Wilson et al., 2020) showed that kratom also
exerts other therapeutic effects besides analgesic properties,
including applications in opioid withdrawal, described in more detail
below.
3.2.2 | Withdrawal and dependence
Twelve in vivo studies (mice, rats or zebrafish) and two in vitro studies
provided evidence for kratom so potential therapeutic use in the
treatment of both opioid (Cheaha et al., 2017; Fakurazi et al., 2013;
Harun et al., 2020; Hassan et al., 2020; Hemby et al., 2019; Jamil
et al., 2013; Khor et al., 2011; Meepong and Sooksawate, 2019;
Wilson et al., 2020; Yue et al., 2018) and alcohol use disorders
(Cheaha et al., 2015; Gutridge et al., 2020; Kumarnsit et al., 2007a;
Vijeepallam et al., 2019), as shown by the effects of the studied
preparations (kratom extracts, LKT, mitragynine and other alkaloids;
p.o. or i.p. or i.v. or intragastrically) in models of induced withdrawal,
drug consumption/replacement, and dependence.
Among the extracts, the MS alkaloid (Cheaha et al., 2015) and
aqueous extract (Kumarnsit et al., 2007a) attenuated ethanol with-
drawal. The methanol extract was found to reduce the ethanol‐
seeking behavior (Vijeepallam et al., 2019), and both extracts (with
or without 7HMG) and alkaloids (e.g., paynantheine, speciogynine,
mitragynine, 7HMG) diminished alcohol intake (Gutridge
et al., 2020). LKT (Wilson et al., 2020) and mitragynine were re-
ported to lessen morphine withdrawal (Cheaha et al., 2017; Harun
et al., 2020; Khor et al., 2011), with Hassan et al. (2020) suggesting
that this mitragynine effect may resemble that produced by meth-
adone and buprenorphine (Hassan et al., 2020). Additionally, mitra-
gynine attenuated morphine dependence as well (Hemby et al., 2019;
Jamil et al., 2013; Meepong and Sooksawate, 2019), and Yue
et al. (2018) demonstrated a reduction by the compound of response
rates in the model of heroin‐induced Conditioned Place Preference
(CPP) (Yue et al., 2018). Further, Fakurazi et al. (2013) found that
mitragynine possesses the potential to reduce morphine tolerance in
a chronic morphine administration model, defined by transcription
factor cAMP response element binding (CREB)'s activation and
the consequent increase in cAMP level's expression (Fakurazi
et al., 2013).
3.2.3 | Other medical conditions
Twenty‐two (15 in vivo in mice, rats or frogs, rabbits and cats, 7 in
vitro) studies, plus four previously described to report also effects in
pain (Macko et al., 1972; Mossadeq et al., 2009) and withdrawal or
dependence (Khor et al., 2011; Kumarnsit et al., 2007a), provided
evidence for kratom's potential therapeutic use in the treatment of
some conditions.
Both mitragynine and MS extracts (p.o. or i.p.) were found to
produce several effects including gastroprotective action (Chit-
trakarn et al., 2018), inhibition of acid gastric secretion (Tsuchiya
et al., 2002), and anti‐inflammatory (Aziddin et al., 2005; Chittrakarn
et al., 2018; Macko et al., 1972; Mossadeq et al., 2009), stress miti-
gating (Hazim et al., 2011; Khor et al., 2011; Vázquez López
et al., 2017), anxiolytic‐like (Hazim et al., 2014; Khor et al., 2011;
Moklas et al., 2013) and antidepressant‐like effects (Idayu
et al., 2011; Kumarnsit et al., 2007a, 2007b), anorectic action
(Chittrakarn et al., 2008; Grewal, 1932b; Kumarnsit et al., 2006,
2007b), antimutagen/anticancer (Ghazali et al., 2011; Goh
et al., 2014), antioxidant (Goh et al., 2014; Grewal, 1932b; Partha-
sarathy et al., 2009; Yuniarti et al., 2020), and muscle relaxant effect
(Chittrakarn et al., 2010). The extract had a more significant action in
terms of muscle relaxation when compared to mitragynine
(Chittrakarn et al., 2010).
Further, only mitragynine was found to have also dose‐
dependent anthelmintic activity (Abdul Aziz et al., 2012), antitus-
sive (Macko et al., 1972), paramoecia killing action, anti‐hypertensive,
and anesthetic effects (Grewal, 1932b), while MS extracts showed to
exert antibacterial (Juanda et al., 2019; Parthasarathy et al., 2009),
bodyweight decreasing and dose‐dependent antidiarrheal (Chit-
trakarn et al., 2008), antipsychotic‐like (Vijeepallam et al., 2016),
antipyretic effects (Salleh et al., 2011) and facilitation of learning
(Senik et al., 2012).
For a complete overview, see Table 1.
3.2.4 | Therapeutic application and safety issues in
humans
Among the 18 clinical studies, three were experimental studies, with
respectively an interventional, a prospective, and a randomized
placebo‐controlled, double‐blind design. 15 were observational with
a cross‐sectional (N = 13) and a retrospective (N = 2) design. All
these clinical studies were performed in Southern East Asia, and
participants were kratom users.
Among the observational studies (Leong Bin Abdullah et al.,
2019a, 2019b, 2020a, 2020b; Saref et al., 2019a, 2019b; Singh
et al., 2014, 2015, 2018a, 2018b, 2018c, 2018d, 2019a, 2019b,
2019c), none reported evidence of therapeutic application. Safety
issues related to chronic kratom use were shown in nine of these
studies. Issues reported were high cholesterol level (Leong Bin
Abdullah et al., 2020a), a slight increase in both HDL and LDL
(cholesterol) values (Singh et al., 2018a), visual episodic memory or
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learning impairment (Singh et al., 2019c), severe‐to‐moderate
dependence (Singh et al., 2014), with severe dependence negatively
affecting physical well‐being (Leong Bin Abdullah et al., 2019a).
Concerns during kratom cessation were physical (e.g., muscle spasms,
pain, watery eyes and nose, fever, diminished appetite, gastrointes-
tinal effects‐diarrhea, constipation‐, and severe fatigue) (Singh
et al. 2014, 2018d, 2019a), and psychological withdrawal symptoms,
for example, sleep problems, restlessness/nervousness, anger (Singh
et al., 2014, 2018d), and mild levels of anxiety and depression (Singh
et al., 2018c). Some of these adverse effects were described as linked
to a greater kratom tea/juice daily consumption (Singh et al., 2018a,
2018c, 2018d, 2019a) or a major daily use frequency (Leong Bin
Abdullah et al., 2020a).
Further, evidence of severe psychosis (Leong Bin Abdullah
et al., 2019b) and electrocardiogram (ECG) alterations (Leong Bin
Abdullah et al., 2020b) was found to be not related to kratom use.
Additionally, kratom was not found to have a negative impact on life
quality (Leong Bin Abdullah et al., 2019a), nor causing any alterations
of hepatic (Leong Bin Abdullah et al., 2020a) or other biochemical
parameters (Singh et al., 2018a), hormones levels (testosterone, FSH
and LH; Singh et al., 2018b), social functioning in a traditional setting
(Singh et al., 2015), motor function, and cognitive profile concerning
attention, working memory, and executive functions (Singh
et al., 2019c).
Among the experimental studies, evidence of potential thera-
peutic applications was shown in two studies. In fact, in the inter-
ventional study performed by Grewal (1932a), participants (N = 5)
were orally administered mitragynine acetate (0.05 g–50 mg) or MS
powdered leaves (0.65, 1.3 g), and kratom was found to reduce heat
sensitivity and electrical resistance of the skin, to improve muscular
work, and to cause dilatation of the skin blood vessels
(Grewal, 1932a). Furthermore, some safety issues were reported by
Grewal (1932a), such as giddiness, slight sight's alterations and
nystagmus, muscle tenseness, pupils contraction, hand/tongue's
tremor, stomach irritation and nausea, sleepiness sensation, and
distorted motor coordination at higher doses (Grewal, 1932a).
However, the adverse effects reported by Grewal (1932a) came from
a small sample (N = 5) and cannot be generalized.
Vicknasingam et al. (2020) did not report any safety issues in
a recent Randomized Controlled Trial (RCT) with participants be-
ing administered three kratom decoction drinks (mitragynine dose
is not described). They found that kratom increased tolerance to
cold‐evoked pain one hour after administration, without reporting
discomforts nor withdrawal symptoms for at least 20 h (Vickna-
singam et al., 2020). Finally, Trakulsrichai et al (2015) performed a
prospective study on 10 participants, which were administered
one dose (range 6.25–11.5 mg) per day for one week and a final
dose on the eighth day (range 6.25–23 mg). This study did not
show any therapeutic application but, in the absence of any
serious adverse effect, reported some minor safety issues after
kratom administration, such as a temporary blood pressure/heart
rate increase and tongue numbness. Other details are provided in
Table 2.
4 | DISCUSSION
To our knowledge, this is the first systematic review that provides an
overview of (pre)clinical evidence of mitragynine/kratom therapeutic
use and safety issues in humans. Among the records included in this
analysis (N = 75), 24% provided data in humans, while 76% supported
its potential therapeutic use in the treatment of either acute and
chronic pain (41%), substance use disorders (25%), such as morphine
withdrawal and dependence, ethanol withdrawal, seeking behavior
and intake; and other medical conditions based on several kratom
effects (46%). Two out of the 18 clinical studies reported evidence of
potential therapeutic application in pain. In contrast, some issues
chronic kratom use related, such as learning impairment, alterations
of cholesterol level, dependence, and withdrawal symptoms, were
reported in 50% of them.
Many plant‐based medicines, including kratom, have historically
been used in tropical regions to treat common health problems (Brown
et al., 2017). However, over the years, its use has been become diffuse
also in Western countries for both recreational and self‐medicating
purposes. Among the latter, the most commonly reported by users is
pain relief (Grundmann, 2017; Schimmel et al., 2020; Singh et al., 2020).
The antinociceptive effects of kratom preparations, such as
mitragynine (Carpenter et al., 2016; Criddle, 2015; Fakurazi
et al., 2013; Foss et al., 2020; Hiranita et al., 2019; Idid et al., 1998;
Macko et al., 1972; Matsumoto et al., 1996a, 1996b; Shamima
et al., 2012; Thongpradichote et al., 1998), LKT (Wilson et al., 2020),
MG Pseudoindoxyl (Takayama et al., 2002), MGM‐9 (Matsumoto
et al., 2008), MGM‐15 and MGM‐16 (Matsumoto et al., 2014), and
7HMG (Matsumoto et al., 2004, 2005, 2006) recently suggested to be
the key mediator of mitragynine's analgesic effects (Kruegel
et al., 2019), may be considered as preclinical evidence of kratom's
potential therapeutic use in pain treatment and would explain why
many users claim this benefit. Further, this therapeutic application is
supported by two clinical studies that found kratom to reduce pain
sensitivity (Grewal, 1932a;Vicknasingamet al., 2020).According to the
evidence reviewed in this paper, kratom was reported to exert anti-
nociceptive effects through a multimodal regulation. This is suggested
to involve spinal and supraspinal delta‐, mu‐ (Matsumoto et al., 2014;
Shamima et al., 2012; Thongpradichote et al., 1998), and potentially
kappa‐opioid receptors (Wilson et al., 2020) together with α‐adren-
ergic receptors (Foss et al., 2020). Other suggested mechanisms un-
derlying these analgesic properties would include descending
noradrenergic and serotoninergic systems (Matsumoto et al., 1996a),
Fos expression in the raphe nucleus (Kumarnsit et al., 2007b), neuronal
Ca2+ channels blockage (Matsumoto et al., 2005; Takayama
et al., 2002), and inhibition of some hyperalgesia mediators involved in
anti‐inflammatory processes (Mossadeq et al., 2009). In a double
connection, it is also suggested that the inhibition of active pain sub-
stances release (Aziddin et al., 2005) and a decreased COX‐2 mRNA/
prostaglandin E₂ production (Utar et al., 2011) would mediate kratom's
anti‐inflammatory effects, which we found in some studies (Aziddin
et al., 2005; Chittrakarn et al., 2018; Macko et al., 1972; Mossadeq
et al., 2009). We also found kratom to show some actions suggested to
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be possibly involved in pain reduction with herbal remedies (For-
ouzanfar and Hosseinzadeh, 2018), such as muscle relaxant effects by
acting on the neuromuscular junction (Chittrakarn et al., 2010), and
antioxidant properties potentially related to phenolic content (Ghazali
et al., 2011;Gohet al., 2014;Grewal, 1932b; Parthasarathyet al., 2009;
Yuniarti et al., 2020).
In preclinical studies, kratom was found to reduce ethanol
(Cheaha et al., 2015; Gutridge et al., 2020; Kumarnsit et al., 2007a;
Vijeepallam et al., 2019) and morphine (Cheaha et al., 2017; Fakurazi
et al., 2013; Harun et al., 2020; Hassan et al., 2020; Hemby
et al., 2019; Jamil et al., 2013; Khor et al., 2011; Meepong and
Sooksawate, 2019; Wilson et al., 2020; Yue et al., 2018) withdrawal
and dependence as well. First, it has been suggested that kratom may
reduce opioid dependence by acting on mu‐ and delta‐opioid re-
ceptors (Harun et al., 2020; Hemby et al., 2019), inducing cAMP
pathway down‐regulation (with CREB would be the basis of tolerance
and dependence), and reducing mRNA mu‐opioid receptor expres-
sion (Fakurazi et al., 2013; Jamil et al., 2013), and/or avoiding the
acquisition/expression of morphine‐induced CPP (Meepong and
Sooksawate, 2019). The mitigation of opioid withdrawal has been
suggested to be dependent on mu‐, delta‐ (Hazim et al., 2011), and
kappa‐opioid receptors, but also both kratom anxiolytic (Khor
et al., 2011; Meepong and Sooksawate, 2019) and antidepressant
activity through the serotonergic system (Cheaha et al., 2017) may be
involved. The latter mechanism is presumed to be also involved in
ethanol withdrawal (Cheaha et al., 2015; Kumarnsit et al., 2007a); the
alcohol intake reduction was described to be mainly mediated by
delta‐opioid receptors (Gutridge et al., 2020).
These findings provide some initial evidence for the therapeutic
use of kratom in the treatment of both opioid and alcohol withdrawal
and dependence, and support the empirical use of kratom in self‐
treating of drugs/opioid detoxification and withdrawal as mainly re-
ported by users (Bowe and Kerr, 2020; Boyer et al., 2008, 2007;
Grundmann et al., 2020; Schimmel et al., 2020; Singh et al., 2020).
Further, among studies conducted in users in our analysis, 12%
showed an association between kratom initiation and reduction in
the prevalence of adverse effects related to opiates (e.g., respiratory
depression, constipation, physical pain) (Saref et al., 2019b), and
either in regular drugs use (Saref et al., 2019a). According to Saref
et al. (2019a), this evidence suggests that kratom may also be a useful
agent, less risky than opioids, for harm‐reduction purposes (Saref
et al., 2019a). This data may be supported by the findings of a recent
study that showed LKT to induce fewer side effects (e.g., physical
dependence/respiratory depression) compared to MOR without
affecting motor activity (Wilson et al., 2020). Similarly, some authors
reported that mitragynine is a compound with a minor addictive
potential (Meepong and Sooksawate, 2019; Thériault et al., 2020;
Yue et al., 2018), when compared to MOR (Cheaha et al., 2017;
Harun et al., 2015), neither it caused physiological dependence
(Harun et al., 2020). Moreover, despite kratom and 7HMG were re-
ported to have rewarding effects (Gutridge et al., 2020), with 7HMG
having a higher abuse potential (Hassan et al., 2019; Sabetghadam
et al., 2013; Yusoff et al., 2016), a recent study found that both
mitragynine and 7HMG did not show rewarding actions in the
intracranial self‐stimulation (Behnood‐Rod et al., 2020).
Furthermore, kratom has also been presumed to act on the
serotoninergic/adrenergic system and dorsal raphe nucleus
(Kumarnsit et al., 2007a, 2007b), and to lessen both corticotrophin‐
releasing factor (CRF) and prodynorphin mRNA expression by
acting on the hypothalamic‐pituitary‐adrenal axis (HPA) in the Cen-
tral Nervous System (CNS) (Idayu et al., 2011; Khor et al., 2011).
These mechanisms are reported to mediate stress mitigating (Hazim
et al., 2011; Khor et al., 2011; Vázquez López et al., 2017), anxiolytic‐
like (Hazim et al., 2014; Khor et al., 2011; Moklas et al., 2013),
and antidepressant‐like effects (Idayu et al., 2011; Kumarnsit
et al., 2007a, 2007b). These effects, together with kratom's
antipsychotic‐like effects through 5‐HT2 and D2 receptors inhibition
(Vijeepallam et al., 2016), may be considered as preclinical evidence
of kratom's potential therapeutic use in psychiatric disorders as well
since many users claim kratom's benefits to self‐treat depression,
anxiety and attention deficit hyperactivity disorder (ADHD) (Bath
et al., 2020; Veltri and Grundmann, 2019). That is linear with the idea
reported in the literature that some plants such as kratom, having an
indole moiety like common antidepressant drugs, might be a potential
alternative plant‐based remedy for treating depression (Hamid
et al., 2017) and psychological disorders (Johnson et al., 2020).
Then, we found kratom to exert therapeutic effects in addi-
tional medical domains. These included a peptic ulcer protective
action (Chittrakarn et al., 2018) and acid gastric secretion inhibition
(Tsuchiya et al., 2002), with a possible indirect anorectic action
(Chittrakarn et al., 2008; Grewal, 1932b; Kumarnsit et al., 2006,
2007b), antidiarrheal effect (Chittrakarn et al., 2008), anthelmintic
(Abdul Aziz et al., 2012), antibacterial effects (Juanda et al., 2019;
Parthasarathy et al., 2009), antipyretic (Salleh et al., 2011), anti-
mutagen/anticancer (Ghazali et al., 2011; Goh et al., 2014), anti-
tussive (Macko et al., 1972), and antihypertensive effect
(Grewal, 1932b), that appear in line with the traditional application
of the plant for treating stomach ailments, diabetes, diarrhea, in-
fections, fever, cough, hypertension (Brown et al., 2017; Eastlack
et al., 2020; Hassan et al., 2013; Kruegel and Grundmann, 2018;
Ramachandram et al., 2019; Saref et al., 2019a; Singh et al., 2017,
2020; Suhaimi et al., 2016; Vicknasingam et al., 2010). It was also
found of potential benefit in treating COVID‐19 symptoms (Meta-
stasio et al., 2020).
Finally, the facilitation of learning through the modulation of
memory consolidation (Senik et al., 2012) may provide preclinical ev-
idence of kratom on nootropic effects. This data was also confirmed in
other preclinical studies where kratom showed cognitive enhancing
properties (Hazim et al., 2011; Ilmie et al., 2015). Further, kratom use
did not seem to have long‐term cognitive effects on users, but it was
found to affect only visual episodic memory causing learning impair-
ment in chronic userswith at least twoyears of use (Singh et al., 2019c).
This latest data is in strong contrastwith preclinical evidence related to
kratom's potential to enhance cognition but appears linear with the
cognitive impairment described in preclinical studies with both chronic
(Apryani et al., 2010; Compton et al., 2014; Hassan et al., 2019; Ismail
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et al., 2017; Yusoff et al., 2016) and acute (10, 30, 100 mg/kg, p.o.)
(Moklas et al., 2013) administration of the preparation. It is possible to
say that findings are inconsistent, and kratom's significant cognitive
impact needs to be further investigated.
On the other side, clinical studies related to therapeutic appli-
cations are lacking as well. In the analyzed studies, most partici-
pants consumed ≥ two‐to‐three glasses of kratom 1–3 times daily
with a mitragynine content ranging between a minimum of 72.5 mg
and a maximum of 434.28 mg. However, data about the consumed
amount was only reported in few studies (Leong Bin Abdullah
et al., 2020b; Saref et al., 2019b; Singh et al., 2014, 2018a, 2018b,
2018d, 2019c).
Further, adverse events such as alterations of cholesterol level,
dependence, and withdrawal symptoms were reported and described
as mild and dependent on higher doses (Singh et al., 2018a, 2018c,
2018d, 2019a) or more frequent use (Leong Bin Abdullah et al.,
2020a, 2020b). This suggests that these adverse events may not
occur at lower doses used with less frequency. These findings confirm
that those who use kratom in traditional settings regularly could
experience kratom cessation related concerns, as previously reported
(Saingam et al., 2016; Vicknasingam et al., 2010), but evidence sug-
gests that most of them self‐manage their symptoms (Singh
et al., 2014, 2015), and experience more tolerable pain when
compared to opioids (Singh et al., 2018d). However, a physical well‐
being impairment has been reported only in severe kratom depen-
dence (Leong Bin Abdullah et al., 2019a). Vicknasingam et al. (2020)
did not find withdrawal symptoms in the observation period (20 h),
and Trakulsrichai et al. (2015) did not describe serious adverse
events in humans.
Case reports in the literature showed other health problems
related to chronic kratom use, such as hepatic damage, endocrino-
logic issues (e.g., hypogonadism and hypothyroidism), neurological
disorders, such as posterior reversible leukoencefalopathy syndrome,
seizure and coma, pulmonary (e.g., acute respiratory distress syn-
drome, ARDS), and cardiovascular problems (Alsarraf et al., 2019;
Anwar et al., 2016; Schimmel and Dart, 2020). However, these con-
cerns were mainly reported by users in Western countries, who be-
sides the potential risks, would stress the plant's beneficial effects as
well.
4.1 | Limitations
Our review has some limitations. First, findings from preclinical studies
are not always comparable due to methodological limitations linked to
the studied compounds/preparations, ways of administration, and the
variability of the extract composition as it may contain other alkaloids
like paynantheine, corynantheidine and speciociliatine, speciogynine,
mitragynaline, and corynantheidaline (Takayama, 2004). Thus, this
limits strong conclusions about the effect of mitragynine on the
investigated domains. Second, all clinical studies were performed in
chronic kratom users, in Southern East Asia, with three out of them
(only one RCT) studying kratom acute effects, while no one tested long
term effects of single/repeated administration nor RCTs have been
conducted in kratom naive participants. Most of the other clinical
studies had a cross‐sectional design, which does not allow a definitive
causal interpretation of a direct link between kratom consumption and
health consequences, providing mainly retrospective information in
terms of kratom's exposure. However, this is not generalizable to the
population that occasionally uses kratom in traditional settings, nor to
those that use it innon‐traditional settings in theWest,whereavailable
kratom products may differ in terms of potency. Moreover, the almost
complete absence of female participants should be considered in
further studies to understand gender‐related variation in metabolism
and pharmacology.
5 | CONCLUSIONS
Taken together, our findings help to explain, but not endorse, the
empirical medical use reported by kratom users in non‐medical
settings in both Asian traditional and Western countries, suggest-
ing that kratom could be a useful aid in the treatment of acute/
chronic pain, opioid and substance use disorders, and psychiatric
disorders. Kratom‐related safety issues must be carefully consid-
ered. Until now, mitragynine and kratom's benefits and safety
profile remain largely anecdotal. More studies should be encour-
aged with different populations, including kratom‐naive users in
controlled clinical settings, to identify better mitragynine and kra-
tom's risks and benefits.
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ADD attention deficit disorder
ADHD attention deficit hyperactivity disorder
ARDS acute respiratory distress syndrome
CNS central nervous system
COX‐2 cyclooxygenase‐2
CPP conditioned place preference
CREB cAMP response element binding
CRF corticotrophin releasing factor
CSA controlled substances act
CYP450 cytochrome P450
D2 dopamine
DEA drug enforcement administration
ECG electrocardiogram
FDA food and drug administration
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